glp 1 is tirzepatide (GLP-1 / GIP) Semaglutide vs Tirzepatide, same medication

Novo Nordisk submitted its application to the FDA to expand the indication for Rybelsus to reduce the risk of MACE in patients with type 2 diabetes and established CVD and/or chronic kidney disease

In SURMOUNT1, tirzepatide shifted body composition and cardiometabolic markers in ways that support strength, mobility, and longterm resilience. Researchers from the SURMOUNT1 program found that tirzepatide was associated with: Average weight loss of about 1521% of starting body weight at higher doses Reductions in waist circumference of roughly 1420 cm, signaling less central and visceral fat About threequarters of weight lost coming from fat mass, with fat mass dropping by around onethird and lean mass by about 10% Meaningful drops in systolic blood pressure and atherogenic lipids, with more participants hitting combined goals for weight, blood pressure, and nonHDL cholesterol versus placebo Improved physical function scores on questionnaires, reflecting easier walking, stair climbing, and daily activity That pattern preferential fat loss, preserved muscle, a smaller waist, and better hemodynamics is exactly what protects balance, strength, and independence, making it one of the clearest ways tirzepatide can support a longer healthspan beyond a lower number on the scale

Real-world dosing errors and how to avoid them This is not theoretical

Eating smaller meals, avoiding high-fat foods, and staying hydrated help manage it

Step 5: Store securely

Mixx compounded: $120